AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3 clinical trial titled A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). The study aims to assess the efficacy and safety of Dato-DXd compared to standard chemotherapy options in patients with specific breast cancer conditions, focusing on progression-free survival (PFS) and overall survival (OS) as primary objectives.
Intervention/Treatment: The trial tests Dato-DXd, an experimental drug administered via IV infusion, against a selection of chemotherapy drugs chosen by investigators, including Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, and Eribulin mesylate, depending on patient history and condition.
Study Design: This interventional study is randomized with a parallel assignment model, where participants are divided into two groups to receive either Dato-DXd or investigator’s choice chemotherapy. The study is open-label, meaning both researchers and participants know which treatment is being administered, with the primary goal of treatment efficacy.
Study Timeline: The study began on May 16, 2022, and is currently active but not recruiting new participants. The last update was submitted on July 9, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
Market Implications: The progress of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, particularly if Dato-DXd demonstrates superior efficacy and safety. Success in this trial could position AstraZeneca favorably against competitors in the oncology sector, potentially leading to increased market share and revenue growth.
The study is ongoing, with further details available on the ClinicalTrials portal.